Circulating biomarkers for prostate cancer (Q36754208)

16 August 2017

1 reference

title

Circulating biomarkers for prostate cancer (English)

1 reference

16 August 2017

0 references

1 reference

Hans Lilja

3

0 references

author name string

Thomas Steuber

series ordinal

1

1 reference

16 August 2017

Pauliina Helo

series ordinal

2

1 reference

16 August 2017

publication date

8 March 2007

1 reference

16 August 2017

published in

World Journal of Urology

1 reference

16 August 2017

volume

25

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

111-119

1 reference

Detection of prostate cancer with a blood-based assay for early prostate cancer antigen

16 August 2017

cites work

1 reference

12 December 2020

Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients

1 reference

12 December 2020

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

12 December 2020

Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.

1 reference

12 December 2020

Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture

1 reference

12 December 2020

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

12 December 2020

Prostate-specific membrane antigen: present and future applications

1 reference

12 December 2020

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen

1 reference

12 December 2020

Autoantibody signatures in prostate cancer

1 reference

12 December 2020

Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) follo

1 reference

12 December 2020

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

12 December 2020

Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood.

1 reference

12 December 2020

Prostate-specific membrane antigen (PSMA): current benefits and future value

1 reference

12 December 2020

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

12 December 2020

Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer

1 reference

12 December 2020

Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

1 reference

12 December 2020

Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy

1 reference

12 December 2020

Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor

1 reference

12 December 2020

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

1 reference

12 December 2020

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy

1 reference

12 December 2020

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum

1 reference

12 December 2020

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen

1 reference

12 December 2020

Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.

1 reference

12 December 2020

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer

1 reference

12 December 2020

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy

1 reference

12 December 2020

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

1 reference

12 December 2020

Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases

1 reference

12 December 2020

Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage

1 reference

12 December 2020

Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

1 reference

12 December 2020

Interleukin-6 polymorphism is associated with more aggressive prostate cancer.

1 reference

12 December 2020

Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial

1 reference

12 December 2020

Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients

1 reference

12 December 2020

A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.

1 reference

12 December 2020

Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.

1 reference

12 December 2020

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

1 reference

12 December 2020

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum

1 reference

12 December 2020

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

1 reference

12 December 2020

Age-specific reference ranges for serum PSA

1 reference

12 December 2020

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer

1 reference

12 December 2020

Antiprostasome antibody titres in benign and malignant prostate disease

1 reference

12 December 2020

Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml

1 reference

12 December 2020

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

1 reference

12 December 2020

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

1 reference

12 December 2020

The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer.

1 reference

12 December 2020

Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin

1 reference

12 December 2020

Measurement of complexed PSA improves specificity for early detection of prostate cancer

1 reference

12 December 2020

Detection of hematogenous micrometastasis in patients with prostate cancer

1 reference

12 December 2020

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

12 December 2020

Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay

1 reference

12 December 2020

Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies

1 reference

12 December 2020

Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen

1 reference

12 December 2020

Screening for prostate cancer with prostate-specific antigen: beware the biases

1 reference

12 December 2020

Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis

1 reference

12 December 2020

Development and external validation of an extended repeat biopsy nomogram

1 reference

12 December 2020

Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.

1 reference

12 December 2020

Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer

1 reference

12 December 2020

Total and Gleason Grade 4/5 Cancer Volumes are Major Contributors of Human Kallikrein 2, Whereas Free Prostate Specific Antigen is Largely Contributed by Benign Gland Volume in Serum From Patients With Prostate Cancer or Benign Prostatic Biopsies

1 reference

12 December 2020

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

1 reference

12 December 2020

10.1007/S00345-007-0160-0

Identifiers

DOI

1 reference

16 August 2017

1 reference